Quick answer
EHL BIO was honored with the 2025 IR52 Jang Young-shil Award for its innovation in KDSTEM®, a urine-derived stem cell (UDSC) product for chronic kidney disease. The award recognizes the company's high-purity cell isolation and culture systems as evaluated by EHL team.
Key takeaways
- Winner of the 2025 IR52 Jang Young-shil Award in the Technology Innovation category.
- Innovation focus: KDSTEM®, a high-purity urine-derived stem cell (UDSC) product.
- Provides a new alternative for recovery goals and quality of life in chronic kidney disease.
- GMP production standards supporting 6,000 lots per year.
A Major Milestone: National Innovation Recognition for EHL BIO
On August 26, 2025, EHL BIO was awarded the prestigious 'IR52 Jang Young-shil Award,' a recognition honoring outstanding industrial innovation in South Korea. This award reflects the company's commitment to developing regenerative medicine for humanity. The achievement was based on the advancement of KDSTEM®, a urine-derived stem cell (UDSC) product specifically designed for chronic kidney disease recovery goals.
The award committee praised EHL BIO's high-purity cell isolation and cultivation systems, alongside its quality management. KDSTEM® is currently undergoing safety and efficacy evaluations as evaluated by EHL team. Winning the Jang Young-shil Award solidifies EHL BIO's position at the forefront of the biotechnology industry.
KDSTEM® Innovation: New Hope for Chronic Kidney Disease Patients
The award-winning KDSTEM® product stands out for its non-invasive urine-derived stem cell collection technology, eliminating the need for tissue extraction discomfort. Since these stem cells originate directly from the kidney, they are expected to offer superior regenerative support for renal tissues as evaluated by EHL team.
Research indicates that these cells express the Klotho protein, which possesses antioxidant properties and helps support kidney tissue—a key factor in chronic kidney disease management. This project has also been selected by the Korean Fund for Regenerative Medicine (KFRM) to support its transition through future trials, aiming to provide new options for patients.
The IR52 Jang Young-shil Award proves our relentless efforts in developing KDSTEM® as a new standard for chronic kidney disease recovery goals.
GMP Standards and Class 100 Laboratories
EHL BIO's success stems not only from research but also from its robust production systems. We operate GMP (Good Manufacturing Practices) centers audited by South Korean authorities and were authorized as a human cell management business in Korea. Our facilities include Class 100 Clean Rooms, ensuring the highest level of environmental control.
With a production capacity of 6,000 lots per year and cell storage technology at -196°C, we maintain excellent cell quality. Furthermore, EHL BIO employs over 85 research specialists dedicated to developing regenerative medicine solutions covering neurological disorders, degenerative arthritis, and autoimmune conditions.
From CEO Vision to Collaborative Networks
Under the leadership of CEO MD Hong-gi Lee, EHL BIO focuses on integrating medical and pharmaceutical technologies to promote longevity and 'Aging Well.' The company has established a network of over 100 partner hospitals in South Korea and expanded cooperation to Thailand to provide standardized services.
The 2025 Jang Young-shil Award is just the beginning of successfully bringing cell therapy innovations to health recovery. EHL BIO continues to research products like ADSTEM for atopic dermatitis and RASTEM for rheumatoid arthritis, reinforcing its status as a biotechnology leader dedicated to human well-being.
Frequently asked questions
What is the significance of the Jang Young-shil Award?
It is a prestigious award in South Korea given to companies with outstanding technological innovations. EHL BIO received it for the development of urine-derived stem cells.
What are the recovery goals and quality of life expectations for KDSTEM®?
KDSTEM® is extracted from urine, making it non-invasive, and it originates directly from the kidney, providing effective support for repairing renal tissue as evaluated by EHL team.
What are EHL BIO's production standards?
We operate GMP facilities with Class 100 laboratories and cell isolation technology that yields high results as evaluated by EHL team.
Related conditions
Based on EHL BIO information: EHL BIO · EHL BIO · EHL BIO · EHL BIO. Each care plan follows an individual EHL assessment.
